PRLD - Prelude Therapeutics Incorporated
NASDAQ
->
Healthcare
->
Biotechnology
Wilmington,
United States
Type: Equity
PRLD price evolution
PRLD
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $31.87 | $28.75 | $29.34 | |
| Short term investments | $152.02 | $177.22 | $207.64 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $156.39 | $182.71 | $205.37 | $235.59 |
| Long term investments | ||||
| Property, plant & equipment | $36.38 | $37.13 | $37.4 | $37.74 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $41.58 | $41.74 | $42.08 | |
| Total investments | $152.02 | $177.22 | $207.64 | |
| Total assets | $197.22 | $224.29 | $247.11 | $277.67 |
| Current liabilities | ||||
| Accounts payable | $5.92 | $6.17 | $5.31 | $4.58 |
| Deferred revenue | $3 | |||
| Short long term debt | $2.74 | $2.19 | $1.48 | |
| Total current liabilities | $22.22 | $23.34 | $17.64 | $21.83 |
| Long term debt | $15.46 | $15.45 | $15.41 | |
| Total noncurrent liabilities | $18.68 | $18.73 | $18.75 | |
| Total debt | $18.2 | $17.64 | $16.89 | |
| Total liabilities | $40.79 | $42.02 | $36.37 | $40.58 |
| Shareholders' equity | ||||
| Retained earnings | -$554.83 | -$522.56 | -$487.82 | -$456.39 |
| Other shareholder equity | $0.17 | -$0.29 | -$0.23 | $0.22 |
| Total shareholder equity | $182.28 | $210.73 | $237.09 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $29.34 | $34.65 | $35.87 | $218.31 |
| Short term investments | $207.64 | $171.12 | $259.4 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $235.59 | $204.38 | $295.12 | $220.81 |
| Long term investments | ||||
| Property, plant & equipment | $37.74 | $6.7 | $5.64 | $2.48 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $42.08 | $16.12 | $9.98 | $2.78 |
| Total investments | $207.64 | $171.12 | $259.4 | |
| Total assets | $277.67 | $220.5 | $305.1 | $223.59 |
| Current liabilities | ||||
| Accounts payable | $4.58 | $6.78 | $7.84 | $3.92 |
| Deferred revenue | ||||
| Short long term debt | $1.48 | $1.83 | $1.74 | |
| Total current liabilities | $21.83 | $21.7 | $19.2 | $11.38 |
| Long term debt | $15.41 | |||
| Total noncurrent liabilities | $18.75 | $3.36 | $0.03 | |
| Total debt | $16.89 | $1.83 | $1.74 | |
| Total liabilities | $40.58 | $25.06 | $19.2 | $11.41 |
| Shareholders' equity | ||||
| Retained earnings | -$456.39 | -$334.56 | -$219.12 | -$107.43 |
| Other shareholder equity | $0.22 | -$1.69 | -$0.71 | |
| Total shareholder equity | $237.09 | $195.44 | $285.9 | $212.18 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $27.41 | $30.33 | ||
| Selling, general & administrative | $6.93 | $7.05 | ||
| Total operating expenses | $37.38 | $34.34 | $37.38 | |
| Operating income | -$34.34 | -$37.38 | ||
| Income from continuing operations | ||||
| EBIT | -$31.43 | -$33.08 | ||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$32.27 | -$31.43 | -$33.08 | |
| Income (for common shares) | -$31.43 | -$33.08 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $103.39 | $92.89 | $86.78 | $48.18 |
| Selling, general & administrative | $28.88 | $30.65 | $26.96 | $10.59 |
| Total operating expenses | $132.28 | $123.54 | $113.73 | $58.76 |
| Operating income | -$132.28 | -$123.54 | -$113.73 | -$58.76 |
| Income from continuing operations | ||||
| EBIT | -$121.83 | -$115.44 | -$111.69 | -$56.93 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$121.83 | -$115.44 | -$111.69 | -$56.93 |
| Income (for common shares) | -$121.83 | -$115.44 | -$111.69 | -$56.93 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$34.74 | -$31.43 | -$33.08 | |
| Operating activities | ||||
| Depreciation | $0.85 | $0.84 | $0.94 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.1 | $5.55 | $5.91 | |
| Total cash flows from operations | -$23.06 | -$31.79 | -$23.58 | |
| Investing activities | ||||
| Capital expenditures | -$0.36 | -$0.29 | -$1.13 | |
| Investments | $26.48 | $31.51 | $8.87 | |
| Total cash flows from investing | $68.07 | $26.12 | $31.22 | $7.74 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.26 | $25.27 | ||
| Net borrowings | -$0.1 | |||
| Total cash flows from financing | -$0.09 | $0.06 | -$0.01 | $25.24 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$14.16 | $3.12 | -$0.58 | $9.39 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$121.83 | -$115.44 | -$111.69 | -$56.93 |
| Operating activities | ||||
| Depreciation | $3.1 | $3.04 | $2.24 | $0.54 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $25.62 | $25.14 | $20.93 | $5.58 |
| Total cash flows from operations | -$107.06 | -$83.73 | -$83.53 | -$46.18 |
| Investing activities | ||||
| Capital expenditures | -$3.51 | -$3.02 | -$2.32 | -$0.62 |
| Investments | -$31.13 | $84.71 | -$261.48 | |
| Total cash flows from investing | -$34.65 | $81.69 | -$263.8 | -$0.62 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $136.41 | $0.81 | $165.2 | $166.72 |
| Net borrowings | -$0.26 | |||
| Total cash flows from financing | $136.4 | $0.81 | $164.9 | $246.23 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$5.31 | -$1.22 | -$182.44 | $199.43 |
News
Fundamentals
| Market cap | $40.66M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 42.18M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.17 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.04 |
| Quick ratio | N/A |